Lv6
1910 积分 2021-10-22 加入
Small Cell Lung Cancer: A Review
1个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC
3个月前
已完结
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non–Small Cell Lung Cancer
3个月前
已完结
Biomarkers of Hyperprogression and Pseudoprogression with Immune Checkpoint Inhibitor Therapy
4个月前
已关闭
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non-Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial
4个月前
已完结
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
4个月前
已完结
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
5个月前
已完结
Redefining Lung Cancer Therapy - A Long-Awaited Shift in Strategy
5个月前
已完结
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
5个月前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
6个月前
已完结
皖公网安备34019202002308
